SCHEMBL6987540

SCHEMBL6987540

N#Cc1ccc(C=O)cc1C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.37
ALDH1A3 P47895 1/20 0.33
HTR2A P28223 1/20 0.33
CTSK P43235 3/20 0.33
SIGMAR1 Q99720 2/20 0.33
CTSS P25774 2/20 0.33
TMEM97 Q5BJF2 1/20 0.33
EBP Q15125 1/20 0.33
AR P10275 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
EGFR P00533 1/20 0.33
CSF1R P07333 1/20 0.32
NOS2 P35228 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25370072 0.92 EGFR (0.35) MAOAMAOBARMEN1ALDH1A1
SCHEMBL15716315 0.85 EGFR (0.37) PTGDR2ALDH1A3HTR2AMEN1ALDH1A1
SCHEMBL15716094 0.80 EGFR (0.38) ALDH1A1HPGDEGFR
SCHEMBL20183968 0.78 ALDH1A1 (0.36) ALDH1A3SIGMAR1TMEM97EBPALDH1A1
SCHEMBL28475060 0.77 HSP90AA1 (0.54) ALDH1A3MEN1ALDH1A1GAAMAPT
SCHEMBL29038963 0.76 MAOA (0.44) MAOAMAOBPTGDR2HTR2ACTSK
SCHEMBL28252844 0.76 PTGDR2 (0.54) MAOAMAOBPTGDR2HTR2ANOS2
SCHEMBL16954306 0.75 MAOA (0.33) MAOAMAOBAR
SCHEMBL16950744 0.75 ALDH1A1 (0.34) MAOAMAOBHTR2AARALDH1A1
SCHEMBL6744755 0.75 KDM4E (0.52) ALDH1A3ALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 MAOA 2136/4885MAOB 1651/4885PTGDR2 3160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.